KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Change in Cash (2016 - 2025)

Gilead Sciences (GILD) has disclosed Change in Cash for 17 consecutive years, with $233.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 95.3% year-over-year to $233.0 million, compared with a TTM value of -$2.4 billion through Dec 2025, down 162.16%, and an annual FY2025 reading of -$2.4 billion, down 162.16% over the prior year.
  • Change in Cash was $233.0 million for Q4 2025 at Gilead Sciences, down from $2.2 billion in the prior quarter.
  • Across five years, Change in Cash topped out at $5.0 billion in Q4 2024 and bottomed at -$2.8 billion in Q2 2025.
  • Average Change in Cash over 5 years is $78.3 million, with a median of $117.0 million recorded in 2023.
  • Peak annual rise in Change in Cash hit 226300.0% in 2024, while the deepest fall reached 353.39% in 2024.
  • Year by year, Change in Cash stood at $976.0 million in 2021, then dropped by 26.95% to $713.0 million in 2022, then plummeted by 46.7% to $380.0 million in 2023, then skyrocketed by 1203.95% to $5.0 billion in 2024, then crashed by 95.3% to $233.0 million in 2025.
  • Business Quant data shows Change in Cash for GILD at $233.0 million in Q4 2025, $2.2 billion in Q3 2025, and -$2.8 billion in Q2 2025.